IMPAKT 2015 is designed for breast cancer researchers and clinicians who have a specific interest in translational research, new agents, molecular and functional diagnostics, biomarkers and cutting-edge research applications in the clinical setting.
The programme can also benefit scientists, medical oncologists, breast surgeons, pathologists, imaging specialists, radiation oncologists, and other professionals involved in breast cancer research.
- The molecular origin of breast cancer and clinical significance of genomic patterns
- Mutations and therapy resistance
- Microenvironment and metastatic cascade in breast cancer
- Translational studies in early stage breast cancer
- The role of chemotherapy in the context of precision medicine
- Triple negative breast cancer: Tackling diversity
- Provide information on the myriad discoveries that already have or will have impact on breast cancer research and treatment in the near future
- Discuss concepts of cellular origin of breast cancer and implications for clinical practice
- Discuss which mutations are clinically relevant in breast cancer and strategies for their identification, as well as therapeutic implications
- Analyse a tumour evolution in the metastatic setting
- Provide an update on strategies to modulate the immune system in breast cancer
- Provide an update on translational research approaches in clinical trials in early stage breast cancer
- Debate on role of chemotherapy in the context of precision medicine
- Elaborate on results from studies in triple negative breast cancer
Benefits of attending
- Receive a high scientific-level overview of ongoing translational research in the field of breast cancer and exchange opinions with breast cancer researchers, scientists and clinicians
- Top expert will put in perspective advances on a molecular level exploited for clinical purposes
- To stay up to date with scientific progress in breast cancer research as the therapeutic road from the laboratory to the clinic shortens
- To focus on premier data and technologies that sharpen the knife of molecular dissection and define the cellular structures that determine responsiveness to novel therapies
- Present your research data to a high-profile audience of international experts, where the focus is on hot topics in breast cancer research which are of interest to multiple disciplines
- Encourages breast cancer team integration with enhanced discussions amongst specialists through the facilitation of networking opportunities
ESMO-MORA: The conference programme has been accredited with 12 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. Learn more about ESMO-MORA recertification.
CME: The IMPAKT Breast Cancer Conference programme has been designated for a maximum of 11 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found online here.
The conference webcasts will include all the session of the official programme, where speaker permission is granted, and will be available here and on OncologyPRO for ESMO Members.